FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Biologics

Routine Vaccine Inspections May be Challenge: GAO

The Government Accountability Office says FDA may be challenged in resuming routine surveillance inspections of vaccine and allergenic manufacturing f...

FDA General

Yale Working with FDA on Trial Diversity

FDA contracts with the Yale School of Medicine to promote clinical trial awareness and access to underrepresented minorities.

Medical Devices

FDA Breast Implant Safety Actions

FDA says it has taken three new actions to strengthen the risk communication about breast implants and help consumers to make informed decisions.

Federal Register

Panel to Review Merck Covid Drug

Federal Register notice: FDA announces an 11/30 Antimicrobial Drugs Advisory Committee meeting to review a Merck Emergency Use Authorization request f...

Federal Register

CDRH Guidance Document Plans for FY 2022

Federal Register notice: FDA announces the Web site location where it will post two lists of guidance documents that CDRH intends to publish in fiscal...

Human Drugs

FDA, Others Working on Rare Disease Gene Therapies

FDA is joining with 16 other organizations to increase effective gene therapies for rare diseases.

Human Drugs

BIMO Inspectors Learn to Rely on Remote Assessments

CDER Office of Compliance director Don Ashley tells the Pharmaceutical Quality Symposium that during the Covid-10 pandemic, more than 70 bioresearch m...

Medical Devices

CDRH Lists FY 2022 Proposed Guidances

FDA publishes two lists of final and draft guidance topics for FY 2022 and a list of final guidances from four years for comment on whether they shoul...

Human Drugs

Comments on Draft PD Cancer Treatment Guidance

Five drug companies comment on an FDA draft guidance on a cancer antibody treatment dosing regimen.

Human Drugs

Novartis Phase 3 Lung Cancer Trial Doesnt Hit Endpoints

Novartis says further evaluation of its lung cancer treatment canakinumab is warranted even though a Phase 3 trial did not meet its primary endpoints.